Status:
COMPLETED
Responsiveness to Dalfampridine-ER Treatment Among Multiple Sclerosis Patients
Lead Sponsor:
Mount Sinai Rehabilitation Hospital
Collaborating Sponsors:
Brown University
Acorda Therapeutics
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
Ampyra (dalfampridine-ER) was approved by the FDA (2010) for improving walking speed in persons with multiple sclerosis. This project seeks to determine if there are other benefits to taking dalfampri...
Detailed Description
Subjects will be evaluated before starting medication, throughout a 14week period after starting D-ER as well as at 12 and 18months following the start date of medication regardless of if they stayed ...
Eligibility Criteria
Inclusion
- Confirmed clinical diagnosis of MS by McDonald criteria
- Prescribed ampyra (dalfampridine) as part of usual care, but have not yet started taking the medication before baseline visit
- Receive MS care at the Mandell MS center
- Cognitively able to understand directions and complete protocol (score of 22 or greater on the MMSE)
- 18 years of age or older
Exclusion
- Already began to take drug prior to baseline research visit
- Not planning to continue care at Mandell Center for at least 14 weeks after initiation of therapy
- Unwilling or unable to complete assessments
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT01399957
Start Date
August 1 2010
End Date
September 1 2015
Last Update
November 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mandell Center for Multiple Sclerosis at the Mount Sinai Rehabilitation Hospital
Hartford, Connecticut, United States, 06112